Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03195400 · ClinicalTrials.gov registry record
Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes
A clinical trial of T2D and IGT - Impaired Glucose Tolerance, sponsored by Yale University.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT03195400 is a study of T2D and IGT - Impaired Glucose Tolerance that has completed, run by Yale University. The registered enrollment target is 100 participants, below the 324-participant average among 3 other T2D trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03195400, a study of T2D and IGT - Impaired Glucose Tolerance, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incretin system and hepatic insulin resistance in obese adolescents. The long-term goal of this study is to generate information on both the genetics as well as the pathophysiology of Type 2 Diabetes in Youth, which ultimately might guide the investigators towards better preventive and treatment avenues.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Oral Glucose Tolerance Test
- DIAGNOSTIC_TEST Hyperglycemic Clamp
- DIAGNOSTIC_TEST Isoglycemic Intravenous Glucose Test
- DIAGNOSTIC_TEST Hyperinsulinemic Euglycemic Clamp and 2H20
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2022-08-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03195400
The ClinicalTrials.gov registry entry for NCT03195400 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 3 other T2D trials with a reported enrollment target (69% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with T2D appearing as the primary indexed condition, and to 4 interventions - of which Oral Glucose Tolerance Test is the first listed.
NCT03195400 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03195400 about?
NCT03195400 is a clinical study titled "Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes". Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incret...
What is the current status of trial NCT03195400?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2017-03-01. Estimated completion is 2022-08-12.
What conditions does trial NCT03195400 study?
This clinical trial studies the following conditions: T2D, IGT - Impaired Glucose Tolerance.
What interventions are being tested in trial NCT03195400?
The interventions under investigation include: Oral Glucose Tolerance Test (DIAGNOSTIC_TEST), Hyperglycemic Clamp (DIAGNOSTIC_TEST), Isoglycemic Intravenous Glucose Test (DIAGNOSTIC_TEST), Hyperinsulinemic Euglycemic Clamp and 2H20 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03195400?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03195400 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T2D
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D
RECRUITING
-
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.